https://orcid.org/0000-0003-4398-2166
References
- Kadoyama K, Tamon A, Okuno Y. Adverse event profile of tigecycline: data mining of the public version of the U.S. food and drug administration adverse event reporting system. Biol Pharm Bull. 2012;35:967–970.
- Rossitto G, Rosi S, Simioni P, et al. Life-threatening coagulopathy and hypofibrinogenemia induced by tigecycline in a patient with advanced liver cirrhosis. Eur J Gastroenterol Hepatol. 2014;26:681–684.
- Pieringer H, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89:1063–1064.
- Sabanis N, Gavriilaki E, Kalaitzoglou A, et al. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis (Lond). 2015;47:743–746.
- McMahan J. Tigecycline-induced coagulopathy. Am J Health Syst Pharm. 2017;74:130–134.
- Wu X, Zhao P. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine. 2017:96 (49).
- Duran F, Emre M. A lesser known side effect of tigecycline: hypofibrinogenemia. Turk J Hematol. 2018;35:75–93.
- Routsi. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2014:45 (1): 90–3.
- Zhang Q, Jing Z. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2014:59 (3): 1650–1655.
- Food and Drug Administration. Medical review of tigecycline. 2005 June.
- Korth-Bradley JM, Matschke K, Muralidharan G, et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol. 2012;52:1379–1387.
- Troy SM, Micalizzi M, Mojaverian P, et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). Abstract 43rd Interscience Conference of Antimicrobial Agents Chemotherapy. 2003, Chicago.